Roche's Enspryng wins FDA approval for thyroid eye disease
Roche's Enspryng wins FDA approval for thyroid eye disease
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
Roche Wins FDA Approval for Enspryng in Thyroid Eye Disease
Roche Holding said the FDA approved Enspryng as a treatment for thyroid eye disease in adults, its second U.S. indication for the drug.
Roche's Genentech Wins FDA Approval for Enspryng to Treat Thyroid Eye Disease
Roche unit Genentech secured FDA approval for Enspryng to treat adults with thyroid eye disease. Enspryng becomes the first and only at-home subcutaneous treatment for the condition, administered by patients or caregivers following training. In SatraGO-2, proptosis response reached 52.9% with Enspryng versus 23.4% with